EE386 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland
Abstract
Authors
L Veijalainen N Lyris PJK Elo A Ferguson D Willems